Biocon teams with PiSA to tap U.S. insulin market

Business Standard – Bangalore-based Biocon entered into an agreement with Laboratorios PiSA of Mexico for the co-development and commercialization of generic recombinant human insulin (rh-insulin) for the US market. This collaboration is a part of Biocon’s strategy to address the large demand for generic rh-insulin in the US, which accounts for over 40 percent of the global sales of $5 billion.

Leave a Reply

Your email address will not be published. Required fields are marked *